Systemic lupus erythematosus: Extent and patterns of off-label use of rituximab for SLE.
Systemic lupus erythematosus: Extent and patterns of off-label use of rituximab for SLE.
复制标题
DOI：
10.1038/nrrheum.2016.191
复制
发表时间：
2016-11-22
期刊：
影响因子：
--
通讯作者：
Sanz I
中科院分区：
文献类型：
--
作者：
Sanz I
尽管来自临床试验的证据相互矛盾，利妥昔单抗仍然被用于系统性红斑狼疮（SLE）的治疗。一项新的研究现在已经调查了这种药物在欧洲用于SLE的情况，包括使用适应症和患者特征。
Despite conflicting evidence from clinical trials, rituximab continues to be used off-label in the treatment of systemic lupus erythematosus (SLE). A new study has now investigated the use of this drug for SLE in Europe, including indications for use and patient characteristics.